By Fineline Cube 
China-based 3SBio Inc. (HKG: 1530) announced this week the registration of the first Phase III clinical study for its SSGJ-707 in patients with advanced PD-L1 positive, locally advanced, or metastatic non-small cell lung cancer (NSCLC) on ClinicalTrials.gov. The study will assess the drug’s efficacy head-to-head against MSD’s anti-PD-1 therapy, Keytruda (pembrolizumab).
SSGJ-707 Development and Licensing
SSGJ-707 was out-licensed to US major Pfizer Inc. (NYSE: PFE) for ex-mainland China rights via a USD 6.05 billion deal. The drug is subject to multiple clinical studies in China, focusing on non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. It has demonstrated significant anti-tumor activity and good safety, both as a monotherapy and in combination with other drugs.
Clinical Trial Timeline
The Phase III study is expected to reach a preliminary conclusion in July 2026. This milestone will further validate SSGJ-707’s potential as a competitive treatment option in the oncology space, particularly for patients with advanced NSCLC.-Fineline Info & Tech